<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03504631</url>
  </required_header>
  <id_info>
    <org_study_id>1001</org_study_id>
    <nct_id>NCT03504631</nct_id>
  </id_info>
  <brief_title>Genotyping and Phenotyping of CYP2D6 Breast Cancer Patients on Tamoxifen</brief_title>
  <official_title>Genotyping and Phenotyping of CYP2D6 as Predictor of Z-endoxifen Plasma Levels in Breast Cancer Patients on Tamoxifen Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Trisakti University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dharmais National Cancer Center Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Trisakti University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is an observational study to determine phenotype and genotype of CYP2D6 as
      predictors of z-endoxifen concentrations in plasma of outgoing patients treated with
      tamoxifen for at least 4 months
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Tamoxifen is an antiestrogen drug with concentration dependent properties, with z-endoxifen
      known as active metabolite. Until know therapeutic range for z-endoxifen to improve treatment
      response was not known. Variation response on tamoxifen can be cause of genetic polymorphism
      CYP2D6 that can be different between interindividul and ethnic.

      The aim of this study is to determine phenotype and genotype of CYP2D6 as predictors of
      z-endoxifen concentrations in plasma of outgoing patients treated with tamoxifen for at least
      4 months
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2017</start_date>
  <completion_date type="Anticipated">December 1, 2018</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Genotype and phenotype of CYP2D6</measure>
    <time_frame>4 months</time_frame>
    <description>Number of subjects with CYP2D6 genotype and phenotype who had steady state level</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Z-endoxifen</measure>
    <time_frame>4 months</time_frame>
    <description>Number of subjects with plasma levels of Z-endoxifen more than 5.9 ng/mL</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">117</enrollment>
  <condition>Breast Cancer Female</condition>
  <arm_group>
    <arm_group_label>Breast cancer patients on tamoxifen</arm_group_label>
    <description>Patients currently on treatment with tamoxifen for at least 4 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <description>no intervention</description>
    <arm_group_label>Breast cancer patients on tamoxifen</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples from breast cancer patients treated with Z-endoxifen were drawn for analysis of
      genotype and phenotype of CYP2D6, as well as the plasma concentration of Z-endoxifen
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Outpatient breast cancer patients on tamoxifen treatment for at least 4 months
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Breast cancer patients on tamoxifen treatment for at least 4 months

        Exclusion Criteria:

          -  Abnormalities in liver markers (AST &gt;2.5 x ULN)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Female only</gender_description>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rianto Setiabudy, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Indonesia University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yenny, MD</last_name>
    <phone>+628159661333</phone>
    <email>yenfarmako@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dharmais hospital</name>
      <address>
        <city>Jakarta</city>
        <state>DKI Jakarta</state>
        <zip>11420</zip>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denni Jokopurwanto, MD, PhD</last_name>
      <phone>+62811153590</phone>
      <email>dennijoko@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <reference>
    <citation>Madlensky L, Natarajan L, Tchu S, Pu M, Mortimer J, Flatt SW, Nikoloff DM, Hillman G, Fontecha MR, Lawrence HJ, Parker BA, Wu AH, Pierce JP. Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes. Clin Pharmacol Ther. 2011 May;89(5):718-25. doi: 10.1038/clpt.2011.32. Epub 2011 Mar 23.</citation>
    <PMID>21430657</PMID>
  </reference>
  <reference>
    <citation>Jager NG, Rosing H, Schellens JH, Linn SC, Beijnen JH. Tamoxifen dose and serum concentrations of tamoxifen and six of its metabolites in routine clinical outpatient care. Breast Cancer Res Treat. 2014 Feb;143(3):477-83. doi: 10.1007/s10549-013-2826-1. Epub 2014 Jan 5.</citation>
    <PMID>24390246</PMID>
  </reference>
  <reference>
    <citation>Tamminga WJ, Wemer J, Oosterhuis B, Brakenhoff JP, Gerrits MG, de Zeeuw RA, de Leij LF, Jonkman JH. An optimized methodology for combined phenotyping and genotyping on CYP2D6 and CYP2C19. Eur J Clin Pharmacol. 2001 May;57(2):143-6.</citation>
    <PMID>11417446</PMID>
  </reference>
  <reference>
    <citation>Desta Z, Ward BA, Soukhova NV, Flockhart DA. Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75. Epub 2004 May 24.</citation>
    <PMID>15159443</PMID>
  </reference>
  <reference>
    <citation>Fotoohi AK, Karim H, Lafolie P, Pohanka A, Ã–stervall J, Hatschek T, Vitols S. Pronounced Interindividual But Not Intraindividual Variation in Tamoxifen and Metabolite Levels in Plasma During Adjuvant Treatment of Women With Early Breast Cancer. Ther Drug Monit. 2016 Apr;38(2):239-45. doi: 10.1097/FTD.0000000000000257.</citation>
    <PMID>26485084</PMID>
  </reference>
  <reference>
    <citation>Hennig EE, Piatkowska M, Karczmarski J, Goryca K, Brewczynska E, Jazwiec R, Kluska A, Omiotek R, Paziewska A, Dadlez M, Ostrowski J. Limited predictive value of achieving beneficial plasma (Z)-endoxifen threshold level by CYP2D6 genotyping in tamoxifen-treated Polish women with breast cancer. BMC Cancer. 2015 Aug 1;15:570. doi: 10.1186/s12885-015-1575-4.</citation>
    <PMID>26232141</PMID>
  </reference>
  <reference>
    <citation>Antunes MV, Linden R, Santos TV, Wallemacq P, Haufroid V, Classen JF, Andreolla H, Costa N, Fontanive TO, Rosa DD. Endoxifen levels and its association with CYP2D6 genotype and phenotype: evaluation of a southern Brazilian population under tamoxifen pharmacotherapy. Ther Drug Monit. 2012 Aug;34(4):422-31. doi: 10.1097/FTD.0b013e318260b46e.</citation>
    <PMID>22777153</PMID>
  </reference>
  <reference>
    <citation>Lei L, Wang X, Wu XD, Wang Z, Chen ZH, Zheng YB, Wang XJ. Association of CYP2D6*10 (c.100C&gt;T) polymorphisms with clinical outcome of breast cancer after tamoxifen adjuvant endocrine therapy in Chinese population. Am J Transl Res. 2016 Aug 15;8(8):3585-92. eCollection 2016.</citation>
    <PMID>27648149</PMID>
  </reference>
  <reference>
    <citation>Hawse JR, Subramaniam M, Cicek M, Wu X, Gingery A, Grygo SB, Sun Z, Pitel KS, Lingle WL, Goetz MP, Ingle JN, Spelsberg TC. Endoxifen's molecular mechanisms of action are concentration dependent and different than that of other anti-estrogens. PLoS One. 2013;8(1):e54613. doi: 10.1371/journal.pone.0054613. Epub 2013 Jan 28.</citation>
    <PMID>23382923</PMID>
  </reference>
  <reference>
    <citation>Bagheri A, Kamalidehghan B, Haghshenas M, Azadfar P, Akbari L, Sangtarash MH, Vejdandoust F, Ahmadipour F, Meng GY, Houshmand M. Prevalence of the CYP2D6*10 (C100T), *4 (G1846A), and *14 (G1758A) alleles among Iranians of different ethnicities. Drug Des Devel Ther. 2015 May 13;9:2627-34. doi: 10.2147/DDDT.S79709. eCollection 2015.</citation>
    <PMID>25999696</PMID>
  </reference>
  <reference>
    <citation>Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. Clin Pharmacokinet. 2009;48(11):689-723. doi: 10.2165/11318030-000000000-00000. Review.</citation>
    <PMID>19817501</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 12, 2018</study_first_submitted>
  <study_first_submitted_qc>April 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 20, 2018</study_first_posted>
  <last_update_submitted>April 23, 2018</last_update_submitted>
  <last_update_submitted_qc>April 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Trisakti University</investigator_affiliation>
    <investigator_full_name>Yenny Farmako</investigator_full_name>
    <investigator_title>Head of Pharmacology</investigator_title>
  </responsible_party>
  <keyword>tamoxifen</keyword>
  <keyword>breast cancer</keyword>
  <keyword>Z-endoxifen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamoxifen</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

